The direct comparison of PSMA- and GRPR-targeting imaging agents in PCa patients (n = 7) demonstrated that both agents accumulate similarly in the identified lesions (with a few exceptions when only one of the agents had a high uptake) and the authors concluded that some patients should benefit from imaging with both agents [15]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.